Education
About Us
Working with TipRanks
Follow Us
Petros Pharmaceuticals (PTPI)
OTHER OTC:PTPI
Total Valuation
Petros Pharmaceuticals has a market cap or net worth of $389.82K. The enterprise value is ―.
Market Cap$389.82K
Enterprise Value―
Share Statistics
Petros Pharmaceuticals has 42,372,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding42,372,260
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Petros Pharmaceuticals’s return on equity (ROE) is 1.92 and return on invested capital (ROIC) is 21749.66%.
Return on Equity (ROE)1.92
Return on Assets (ROA)-1.35
Return on Invested Capital (ROIC)21749.66%
Return on Capital Employed (ROCE)2.39
Revenue Per Employee284.00K
Profits Per Employee-795.49K
Employee Count18
Asset Turnover0.48
Inventory Turnover0.90
Valuation Ratios
The current PE Ratio of Petros Pharmaceuticals is ―. Petros Pharmaceuticals’s PEG ratio is 0.12.
PE Ratio―
PS Ratio15.46
PB Ratio-10.59
Price to Fair Value-10.59
Price to FCF-30.09
Price to Operating Cash Flow-0.19
PEG Ratio0.12
Income Statement
In the last 12 months, Petros Pharmaceuticals had revenue of 5.11M and earned -14.32M in profits. Earnings per share was -3.34.
Revenue5.11M
Gross Profit3.90M
Operating Income-17.68M
Pretax Income-14.32M
Net Income-14.32M
EBITDA-10.81M
Earnings Per Share (EPS)-3.34
Cash Flow
In the last 12 months, operating cash flow was -4.84M and capital expenditures -5.45K, giving a free cash flow of -4.84M billion.
Operating Cash Flow-4.84M
Free Cash Flow-4.84M
Free Cash Flow per Share-0.11
Dividends & Yields
Petros Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.40
52-Week Price Change-99.86%
50-Day Moving Average0.02
200-Day Moving Average0.36
Relative Strength Index (RSI)0.39
Average Volume (3m)352.83K
Important Dates
Petros Pharmaceuticals upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Petros Pharmaceuticals as a current ratio of 0.40, with Debt / Equity ratio of 0.00%
Current Ratio0.40
Quick Ratio0.33
Debt to Market Cap0.09
Net Debt to EBITDA-0.34
Interest Coverage Ratio-31.52
Taxes
In the past 12 months, Petros Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Petros Pharmaceuticals EV to EBITDA ratio is -7.65, with an EV/FCF ratio of -31.49.
EV to Sales16.18
EV to EBITDA-7.65
EV to Free Cash Flow-31.49
EV to Operating Cash Flow-31.78
Balance Sheet
Petros Pharmaceuticals has $6.07M in cash and marketable securities with $0.00 in debt, giving a net cash position of $6.07M billion.
Cash & Marketable Securities$6.07M
Total Debt$0.00
Net Cash$6.07M
Net Cash Per Share$0.14
Tangible Book Value Per Share-$1.33
Margins
Gross margin is 63.50%, with operating margin of -345.84%, and net profit margin of -280.10%.
Gross Margin63.50%
Operating Margin-345.84%
Pretax Margin-280.10%
Net Profit Margin-280.10%
EBITDA Margin-211.54%
EBIT Margin-269.13%
Analyst Forecast
The average price target for Petros Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―